J-ALEX: objective tumour response
*In patients with measurable lesion assessed by IRF at
baseline
Nokihara, et al, ASCO 2016 (Abs. 9008)
Waterfall plot* assessed
by IRF
CR or PR
SD, PD or NE
Alectinib
(n=83)
-
10
0
0
-20
-60
-40
-80
Crizotinib
(n=90)
-
10
0
0
-20
-60
-40
-80
% change from baseline
% change from baseline
ORR* assessed by IRF
Alectinib
(n=83)
Crizotinib
(n=90)
ORR, %
91.6
78.9
INDICACIÓN NO APROBADA, EN INVESTIGACIÓN
